Sun Pharma soon to file an application for a new drug with USFDA in two to three years, said Mr.Dilip Shanghvi, Managing director.
The firm's research arm SPARC (Sun Pharma Advanced Research Company) is currently working on three new drugs that are currently under clinical trial stage, he added.
"A few years back, we decided to separate our innovative business in a company called SPARC. That company has now three products undergoing clinical trials. And hopefully in the next two to three years, we should have our own new product registered in the US," said Shanghvi.
He, however, did not elaborate on the therapeutic areas on which those three chemical entities are under research.
The company has around 1,800 research scientists working in multiple R&D centers with expertise in developing generics, difficult to make technology intensive products, Active Pharmaceutical Ingredients (APIs), Novel Drug Delivery Systems (NDDS) and New Chemical Entities (NCEs). The company spends about 6 percent of its revenues on Research and Development.